Enliven Treateutics(ELVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ELVN Enliven Treateutics

Post-Mkt 07-02 19:01:58 EDT

49.82

+1.06

+2.17%

盘后50.81

+0.99+1.99%

17:29 EDT

High50.21	Low47.45	Vol853.72K
Open48.76	D1 Closing48.76	Amplitude5.66%
Mkt Cap3.56B	Tradable Cap2.75B	Total Shares71.44M
T/O42.29M	T/O Rate1.55%	Tradable Shares55.26M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ELVN","market":"US","secType":"STK","nameCN":"Enliven Treateutics","latestPrice":49.82,"timestamp":1783022400000,"preClose":48.76,"halted":0,"volume":853716,"hourTrading":{"tag":"盘后","latestPrice":50.81,"preClose":49.82,"latestTime":"17:29 EDT","volume":130300,"amount":6493126.1481,"timestamp":1783027758479,"change":0.99,"changeRate":0.019872,"amplitude":0.021076},"delay":0,"changeRate":0.021739130434782657,"floatShares":55255000,"shares":71438300,"eps":-1.654577,"marketStatus":"Post-Mkt","change":1.06,"latestTime":"07-02 19:01:58 EDT","open":48.76,"high":50.2095,"low":47.45,"amount":42286272.010308,"amplitude":0.056594,"askPrice":50.81,"askSize":39,"bidPrice":49.76,"bidSize":48,"shortable":3,"etf":0,"ttmEps":-1.654577,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1783036800000},"marketStatusCode":4,"adr":0,"listingDate":1583985600000,"exchange":"NASDAQ","adjPreClose":48.76,"preHourTrading":{"tag":"盘前","latestPrice":48.99,"preClose":48.76,"latestTime":"09:24 EDT","volume":311,"amount":15268.528828,"timestamp":1782998699112,"change":0.23,"changeRate":0.004717,"amplitude":0.01128},"postHourTrading":{"tag":"盘后","latestPrice":50.81,"preClose":49.82,"latestTime":"17:29 EDT","volume":130300,"amount":6493126.1481,"timestamp":1783027758479,"change":0.99,"changeRate":0.019872,"amplitude":0.021076},"volumeRatio":0.302325,"impliedVol":0.6529,"impliedVolPercentile":0.5339},"requestUrl":"/m/hq/s/ELVN/wiki","defaultTab":"wiki","newsList":[{"id":"2646442758","title":"Orbimed Advisors Reports Enliven Therapeutics Common Stock Sale Worth $38.02 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2646442758","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646442758?lang=en_us&edition=fundamental","pubTime":"2026-06-25 07:20","pubTimestamp":1782343225,"startTime":"0","endTime":"0","summary":"OrbiMed Advisors reports Enliven Therapeutics common stock sale worth $38.02 millionOrbiMed Advisors, a 10% owner of Enliven Therapeutics, reported selling 860,123 common shares on June 22, 2026.Sales","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDL7zZgZk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Orbimed Advisors Reports Enliven Therapeutics Common Stock Sale Worth $38.02 Million","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645000856","title":"Enliven Therapeutics CMO Helen Louise Collins disposes of USD 217,816 in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2645000856","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645000856?lang=en_us&edition=fundamental","pubTime":"2026-06-23 05:12","pubTimestamp":1782162752,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics Chief Medical Officer Helen Louise Collins exercised options for 5,000 shares at USD 2.48 on June 17, 2026.Collins sold 5,000 shares the same day at weighted average prices of about USD 42.83 to USD 44.74.Directly held common shares fell to 25,000 following the transactions.Stock options held rose to 121,268, with an exercise price of USD 2.48.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL3mGLVs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Enliven Therapeutics CMO Helen Louise Collins disposes of USD 217,816 in common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644720981","title":"OrbiMed Advisors reports $12.67 million Enliven Therapeutics common stock sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2644720981","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644720981?lang=en_us&edition=fundamental","pubTime":"2026-06-18 07:46","pubTimestamp":1781739970,"startTime":"0","endTime":"0","summary":"OrbiMed Advisors, a more-than-10% owner of Enliven Therapeutics, disclosed sales of common stock on June 15, 2026.OrbiMed Genesis Master Fund sold 9,086 shares at $45.02, cutting its stake to 245,728 shares.OrbiMed Private Investments VII sold 272,322 shares at $45.02, reducing its holding to 7,388,902 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL9hqHNn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"OrbiMed Advisors reports $12.67 million Enliven Therapeutics common stock sale","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643290786","title":"Enliven Therapeutics Closes Upsized $460 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2643290786","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643290786?lang=en_us&edition=fundamental","pubTime":"2026-06-16 05:01","pubTimestamp":1781557291,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics  said Monday it closed an upsized underwritten public offering that raised about $460 million in gross proceeds.The offering included 10.53 million common shares, including the full exercise of the underwriters' option to buy an additional 1.6 million shares, priced at $37.50 each, and 1.73 million pre-funded warrants sold in lieu of common stock to certain investors.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ELVN","LENZ","BK4007","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643309786","title":"Enliven Therapeutics closes upsized public offering, raises USD 460 million gross","url":"https://stock-news.laohu8.com/highlight/detail?id=2643309786","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643309786?lang=en_us&edition=fundamental","pubTime":"2026-06-16 04:40","pubTimestamp":1781556026,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics closed an upsized underwritten public offering of 10,533,334 common shares priced at USD 37.5 each.Deal included full exercise of the underwriters’ option for 1,600,000 additional common shares.Issued pre-funded warrants for 1,733,333 shares at USD 37.499 each, with a USD 0.001 per share exercise price.Gross proceeds totaled about USD 460 million before underwriting discounts, commissions, and offering expenses.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL4vb6JG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643017442","title":"Jefferies Remains a Buy on Enliven Therapeutics (ELVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643017442","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643017442?lang=en_us&edition=fundamental","pubTime":"2026-06-15 22:20","pubTimestamp":1781533238,"startTime":"0","endTime":"0","summary":"In a report released today, from Jefferies maintained a Buy rating on Enliven Therapeutics, with a price target of $59.00. Currently, the analyst c...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-remains-a-buy-on-enliven-therapeutics-elvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-remains-a-buy-on-enliven-therapeutics-elvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","ELVN","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643527222","title":"Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Twist Bioscience (TWST)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643527222","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643527222?lang=en_us&edition=fundamental","pubTime":"2026-06-15 18:00","pubTimestamp":1781517639,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Enliven Therapeutics (ELVN) and Twist Bioscience (TW...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-enliven-therapeutics-elvn-twist-bioscience-twst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-enliven-therapeutics-elvn-twist-bioscience-twst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","ELVN","BK4139","BK4007","BK4588","TWST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643680297","title":"Why Is Enliven Therapeutics Stock (ELVN) Up Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2643680297","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643680297?lang=en_us&edition=fundamental","pubTime":"2026-06-13 02:22","pubTimestamp":1781288573,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics stock was up on news of an upsized public offering.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-is-enliven-therapeutics-stock-elvn-up-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-is-enliven-therapeutics-stock-elvn-up-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","BK4539","ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643639294","title":"Enliven rises 9.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643639294","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643639294?lang=en_us&edition=fundamental","pubTime":"2026-06-13 00:08","pubTimestamp":1781280534,"startTime":"0","endTime":"0","summary":"Enliven (ELVN) is up 9.9%, or $4.01 to $44.37. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/enliven-rises-9-9-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/enliven-rises-9-9-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642291885","title":"BUZZ-Enliven soars after boosted equity raise for leukemia drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2642291885","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642291885?lang=en_us&edition=fundamental","pubTime":"2026-06-12 23:16","pubTimestamp":1781277387,"startTime":"0","endTime":"0","summary":"BUZZ-Enliven soars after boosted equity raise for leukemia drugUpdates stock activity** Enliven Therapeutics' ELVN.O shares reverse premarket losses and soar on Fri after upsized $400 mln follow-on priced** ELVN stock up 12.1% at $45.23 after hitting a six-week high** Biopharma firm late Thurs sold ~8.9 mln shares and pre-funded warrants to buy ~1.7 mln shares at $37.50** Offering size increased from $250 mln** Stock finished up ~9% at $40.36 on Thurs after co's leukemia drug, ELVN-001, showed encouraging early-stage results** Co intends to use net proceeds from offering to advance ELVN-001 in ongoing and planned clinical trials, among other purposes, per the prospectus** Jefferies, Goldman Sachs, Morgan Stanley and Barclays joint bookrunners, along with Mizuho** Burlingame, California-based Enliven has 60.9 mln shares outstanding** With the move, stock has nearly tripled YTD** All 12 analysts rate the stock \"strong buy\" or \"buy\"; median PT $59.50, according to LSEG data","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nL6N42K0WG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","ELVN","BK4552","IE00BSNM7G36.USD","GSX","BK4127","LU0106831901.USD","LU0048573561.USD","LU1668664300.SGD","LU0345770308.USD","LU1868837136.USD","LU0251142724.SGD","LU0868494617.USD","LU0942090050.USD","LU1868836757.USD","LU2237443465.HKD","IE0004091025.USD","LU2750360641.GBP","BK4007","LU2471134523.USD","LU1791807156.HKD","LU2750360997.AUD","LU2265009873.SGD","LU2237443978.SGD","LU1894683348.USD","BK4504","BK4516","JEF","LU2237438978.USD","IE00B19Z3581.USD","BK4559","IE0004086264.USD","IE0034235188.USD","BK4533","LU0251131958.USD","LU0061475181.USD","LU0742534661.SGD","LU1868837300.USD","LU1804176565.USD","IE00BFXG1179.USD","IE0002270589.USD","LU1894683264.USD","BK4550","LU0345770993.USD","LU2237443549.SGD","LU1868836591.USD","BK4585","LU1868836914.USD","BK4588","LU0096364046.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642958942","title":"Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Friday Ahead of SpaceX Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2642958942","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642958942?lang=en_us&edition=fundamental","pubTime":"2026-06-12 21:15","pubTimestamp":1781270103,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2% and the actively traded Invesco QQQ Trust (QQQ) fell 0.3% in Friday's premarket activity, ahead of the debut of Elon Musk","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADBE","SPCX","GLD","IYH","XSD","FDN","USO","IYW","RKLB","VIS","XRT","IYK","IYE","IVV","SLV","IYJ","DXYZ","BCS","FAZ","EETH","SPAL","XLP","RTH","VG","SPY","XLV","XLK","IGM","SOXX","SPCU","FAS","SPY.AU","XLF","IBB","BITO","XLE","SNK","RTH.AU","XOVR","VHT","XLI","EQR","BETH","ELVN","LEN","VDC","XLY","VHT.AU","UNG","QQQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642264760","title":"Enliven Therapeutics Prices $400 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2642264760","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642264760?lang=en_us&edition=fundamental","pubTime":"2026-06-12 18:21","pubTimestamp":1781259681,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics  priced an upsized public offering of 8.9 million shares at $37.50 per share and pre-funded warrants to purchase up to 1.73 million shares at $37.499 each, the company said.The offering, expected to close Monday, is expected to raise gross proceeds of around $400 million, the company said.The company has also granted underwriters a 30-day option to purchase up to 1.6 million additional shares, it said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4007","BK4139","ELVN","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642256142","title":"BRIEF-Enliven Therapeutics Prices 8.9 Million Shares At $37.50 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2642256142","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642256142?lang=en_us&edition=fundamental","pubTime":"2026-06-12 10:41","pubTimestamp":1781232100,"startTime":"0","endTime":"0","summary":"BRIEF-Enliven Therapeutics Prices 8.9 Million Shares At $37.50 Per ShareJune 11 (Reuters) - Enliven Therapeutics Inc ELVN.O:ENLIVEN THERAPEUTICS ANNOUNCES PRICING OF UPSIZED PUBLIC OFFERING OF COMMON ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nTUA1JNL9L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642825616","title":"Enliven Therapeutics prices upsized public offering at $37.5 per share, targets $400 million gross proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2642825616","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642825616?lang=en_us&edition=fundamental","pubTime":"2026-06-12 10:40","pubTimestamp":1781232018,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics priced an upsized underwritten public offering of 8,933,334 common shares at USD 37.5 per share.Offering also includes pre-funded warrants for up to 1,733,333 shares at USD 37.499 each, with a USD 0.001 exercise price.Gross proceeds expected at about USD 400 million, before underwriting discounts and offering expenses.Closing expected on or about June 15, 2026, subject to customary conditions.Underwriters have a 30-day option to buy up to 1,600,000 additional common shares at the offering price, less discounts.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL885nV9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642256149","title":"Enliven: Prices 8.9 Mln Shares at $37.50 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2642256149","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642256149?lang=en_us&edition=fundamental","pubTime":"2026-06-12 10:40","pubTimestamp":1781232002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nTUA1JNL9L:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642237377","title":"BRIEF-Enliven Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2642237377","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642237377?lang=en_us&edition=fundamental","pubTime":"2026-06-12 06:14","pubTimestamp":1781216074,"startTime":"0","endTime":"0","summary":"BRIEF-Enliven Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded WarrantsJune 11 (Reuters) - Enliven Therapeutics Inc ELVN.O:ENLIVEN THERAPEUTICS ANNOUNCES PROPOSED PUBLIC ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nTUA23LFGP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642231146","title":"Enliven Therapeutics launches USD 250 million stock, pre-funded warrant offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2642231146","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642231146?lang=en_us&edition=fundamental","pubTime":"2026-06-12 04:07","pubTimestamp":1781208427,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics launched an underwritten public offering targeting USD 250 million of common stock or pre-funded warrants.Underwriters hold a 30-day option to buy up to an additional USD 37.5 million of common stock.Jefferies, Goldman Sachs, Morgan Stanley, Barclays lead the deal; Mizuho is also a book-running manager.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDLc4N21q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131342.USD","LU1078025761.USD","LU0251131958.USD","LU1244550221.USD","LU0882574139.USD","LU1868836591.USD","LU1804176565.USD","LU0210528500.USD","LU2023251221.USD","IE00BFXG1179.USD","LU1363072403.SGD","IE00BSNM7G36.USD","LU0314104364.USD","LU0251142724.SGD","IE0004086264.USD","LU0047473722.EUR","BARC.UK","LU0987226296.USD","LU1035777561.USD","LU2111349929.HKD","LU1074936037.SGD","LU2237438978.USD","LU1732800096.USD","LU1244550494.USD","LU1868836914.USD","LU1064927863.SGD","ELVN","LU1988902786.USD","BK4585","LU0868494617.USD","LU2237443549.SGD","LU1894683264.USD","GSX","LU0742534661.SGD","LU2271345857.HKD","BK4581","LU0345770993.USD","LU0795875169.SGD","LU1989772923.USD","LU0096364046.USD","LU1791807156.HKD","LU2264538146.SGD","IE00BKVL7J92.USD","LU2089284900.SGD","LU1548497426.USD","LU0047473722.SGD","LU0267386448.USD","LU0006306889.USD","LU1720051017.SGD","LU1989772840.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642231909","title":"Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2642231909","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642231909?lang=en_us&edition=fundamental","pubTime":"2026-06-12 04:05","pubTimestamp":1781208301,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nTUA23LFGP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642028028","title":"Boris Peaker Reiterates Buy Rating and $45 Price Target on ELVN-001 After Strong Phase 1b CML Data Support Best-in-Class Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2642028028","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642028028?lang=en_us&edition=fundamental","pubTime":"2026-06-11 22:15","pubTimestamp":1781187334,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Boris Peaker has reiterated their bullish stance on ELVN stock, giving a Buy rating on June 9. Boris Peaker has given his Buy ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/boris-peaker-reiterates-buy-rating-and-45-price-target-on-elvn-001-after-strong-phase-1b-cml-data-support-best-in-class-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/boris-peaker-reiterates-buy-rating-and-45-price-target-on-elvn-001-after-strong-phase-1b-cml-data-support-best-in-class-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642328040","title":"Enliven rises 14.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642328040","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642328040?lang=en_us&edition=fundamental","pubTime":"2026-06-11 22:08","pubTimestamp":1781186886,"startTime":"0","endTime":"0","summary":"Enliven (ELVN) is up 14.8%, or $5.48 to $42.48. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial new...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/enliven-rises-14-8-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/enliven-rises-14-8-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.enliventherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0207},{"period":"1month","weight":0.2999},{"period":"3month","weight":0.2557},{"period":"6month","weight":2.1377},{"period":"1year","weight":1.4814},{"period":"ytd","weight":2.1662}],"compareEarnings":[{"period":"1week","weight":0.0171},{"period":"1month","weight":-0.0168},{"period":"3month","weight":0.1371},{"period":"6month","weight":0.0916},{"period":"1year","weight":0.2074},{"period":"ytd","weight":0.0936}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.026887},{"month":2,"riseRate":0.666667,"avgChangeRate":0.05311},{"month":3,"riseRate":0.666667,"avgChangeRate":0.048411},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.063791},{"month":5,"riseRate":0.285714,"avgChangeRate":0.136586},{"month":6,"riseRate":0.857143,"avgChangeRate":0.068871},{"month":7,"riseRate":0.142857,"avgChangeRate":-0.096104},{"month":8,"riseRate":0.5,"avgChangeRate":-0.03666},{"month":9,"riseRate":0.5,"avgChangeRate":0.118476},{"month":10,"riseRate":0.5,"avgChangeRate":0.124766},{"month":11,"riseRate":0.166667,"avgChangeRate":0.036396},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.10748}],"exchange":"NASDAQ","name":"Enliven Treateutics","nameEN":"Enliven Treateutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Enliven Treateutics(ELVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Enliven Treateutics(ELVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Enliven Treateutics,ELVN,Enliven Treateutics股票,Enliven Treateutics股票老虎,Enliven Treateutics股票老虎国际,Enliven Treateutics行情,Enliven Treateutics股票行情,Enliven Treateutics股价,Enliven Treateutics股市,Enliven Treateutics股票价格,Enliven Treateutics股票交易,Enliven Treateutics股票购买,Enliven Treateutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Enliven Treateutics(ELVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Enliven Treateutics(ELVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}